Gaboxadol. Lundbeck/Merck.
H Lundbeck A/S, in collaboration with Merck & Co Inc, is developing gaboxadol, a GABAA agonist, for the potential treatment of sleep disorders. The compound is currently undergoing phase III clinical trials.
Actelion Ltd, Innovation Center, Allschwil, Switzerland. richard.huckle@actelion.com
Richard
R
Huckle
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry; D018755:GABA Agonists; D006801:Humans; D007555:Isoxazoles / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D015394:Molecular Structure; D015337:Multicenter Studies as Topic; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013557:Switzerland
D018755:GABA Agonists; D007555:Isoxazoles; C015542:gaboxadol